| Metric | Value ($ M) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 0.22 | 96.7% | 96.5% |
| Total Income | 0.22 | 96.7% | 96.5% |
| Expenditure | 6.19 | 42.6% | 33.7% |
| PBT | -5.04 | 56.2% | 59.5% |
| Net Profit | -5.05 | 56.2% | 59.3% |
| OPM | — | ||
| NPM | — | ||
| EPS | -1.32 | 68.0% | 560.0% |
Lifeward Reports Q3 2026 Financial Results and Provides Business Update
13 Nov 2026 · 13 Nov, 8:01 pm
Summary
Lifeward Ltd. reported third quarter 2026 financial results, with total revenue decreasing 12% year-over-year to $5.4 million, primarily due to a decline in ReWalk sales as the company transitions to a channel-partner model. However, AlterG revenue showed strong growth, increasing 18% to $3.6 million. The company experienced a lower gross margin of 27.4% compared to 43.7% in the prior year quarter, attributed to various cost factors and revenue sharing. Net loss widened to $5.1 million, or $1.32 per share. Management highlighted the transitional nature of the quarter, emphasizing the strategic shift for ReWalk to expand patient access and accelerate long-term revenue growth.
Key Highlights
- 1
AlterG revenue increased 18% year-over-year to $3.6 million in the third quarter of 2026, marking the second consecutive quarter of double-digit growth.
- 2
The Company is transitioning ReWalk to a capital-efficient channel-partner distribution model to expand patient access and support long-term revenue growth.
- 3
Total revenue for the third quarter of 2026 was $5.4 million, a decrease of 12% compared to $6.2 million in the third quarter of 2025.
- 4
Gross margin was 27.4% during the third quarter of 2026, compared to 43.7% in the third quarter of 2025, primarily due to adverse foreign exchange rates, higher freight costs, tariffs, and revenue sharing expenses.
- 5
Net loss for the third quarter of 2026 was $5.1 million, or $1.32 per share, compared to a net loss of $3.2 million, or $2.37 per share, in the third quarter of 2025.
- 6
Unrestricted cash and cash equivalents stood at $4.5 million as of September 30, 2026.
Management Comments
Josh Hexter
The third quarter was a transitional quarter for Lifeward, marked by continued AlterG growth as we move into the advanced stages of transitioning ReWalk to a channel-partner distribution model. Moving away from direct sales can create timing gaps in the near term, but we believe partnering with established providers that already reach patients nationwide is the right path to significantly expand access to ReWalk and accelerate revenue growth over the long term.
Informational and educational content only. Not investment advice.